Vraylar (Cariprazine) During Breastfeeding
Vraylar should not be used during breastfeeding due to lack of safety data in humans and the serious potential risks to the infant from antipsychotic exposure. The FDA label explicitly states that "lactation studies have not been conducted to assess the presence of cariprazine in human milk, the effects on the breastfed infant, or the effects on milk production," and only notes that cariprazine is present in rat milk 1.
Key Evidence and Reasoning
FDA Label Guidance (Highest Priority)
The official Vraylar prescribing information provides clear direction that:
- No human lactation data exists for cariprazine
- Animal studies show the drug is present in rat milk
- The label recommends that "the development and health benefits of breastfeeding should be considered along with the mother's clinical need for VRAYLAR and any potential adverse effects on the breastfed infant" 1
This is regulatory language indicating caution and lack of established safety, not approval for use.
Why This Matters for Infant Safety
Antipsychotics carry significant risks to breastfed infants:
- Cariprazine has a very long half-life (1-3 weeks for active metabolites), meaning it accumulates in both mother and potentially infant over time
- The drug causes sedation, extrapyramidal symptoms, and metabolic effects in adults—effects that would be particularly dangerous in infants with immature hepatic metabolism 1
- Neonates exposed in utero have shown extrapyramidal symptoms and withdrawal symptoms requiring prolonged hospitalization 1
Practical Clinical Approach
If a breastfeeding mother requires antipsychotic treatment:
First-line alternatives: Consider antipsychotics with better lactation safety profiles (quetiapine, olanzapine have more data, though still require caution) 2
If cariprazine is clinically essential (e.g., patient stabilized on it during pregnancy):
- Recommend formula feeding instead of breastfeeding
- Do not attempt "pump and dump" strategies—cariprazine's long half-life makes this ineffective
- If mother insists on breastfeeding, infant requires close monitoring for: sedation, poor feeding, extrapyramidal symptoms, and developmental delays
Timing considerations: The AAP guideline emphasizes that most maternal medications are compatible with breastfeeding 3, but this applies to well-studied drugs—cariprazine is not among them
Critical Pitfalls to Avoid
- Do not assume safety based on other antipsychotics: Each has unique pharmacokinetics
- Do not rely on "low milk transfer" assumptions: No human data exists to support this for cariprazine
- Do not underestimate accumulation risk: The active metabolites (DCAR, DDCAR) have elimination half-lives of 1-3 weeks 1
The Bottom Line
While general breastfeeding guidelines support medication use when benefits outweigh risks 3, 4, cariprazine lacks the safety data needed to make this determination. The combination of no human lactation studies, very long half-life, serious potential adverse effects, and availability of alternatives makes breastfeeding inadvisable during Vraylar treatment. Prioritize either switching to a better-studied antipsychotic or discontinuing breastfeeding to protect infant safety while maintaining maternal mental health treatment.